First Sponsor (ADN) H1 2024 earnings summary
Event summary combining transcript, slides, and related documents.
H1 2024 earnings summary
29 Oct, 2026Executive summary
H1 2024 revenue rose 27.2% to S$172.9m; profit attributable to equity holders increased 12.4% to S$11.9m despite higher net financing costs.
European property income strengthened, while PRC development pre-sales remained muted amid weak market sentiment.
Financial highlights
Revenue increased 27.2% to S$172.873m; gross profit rose 9.8% to S$71.8m, while cost of sales grew 43.4% to S$101.1m.
PBT rose 158.5% to S$32.4m; profit attributable to equity holders increased 12.4% to S$11.924m from S$10.605m.
Net income was S$14.9m versus S$7.8m; operating income rose to S$47.1m from S$27.5m, while net finance costs climbed 81.8% to S$21.1m.
PBT benefited from a S$10.6m fair-value gain on reclassifying Plot E1 retail podium and improved associate/JV results; net derivative fair-value losses were S$43.8m.
Basic EPS was 1.07 cents versus 1.15 cents, mainly reflecting additional shares issued on warrant exercises.
Outlook and guidance
PRC project handovers are expected through FY2024 and 2025; advanced construction stages are expected to keep cash-flow burden manageable.
Completion pipeline includes Puccini Milan and Prins Hendrikkade in FY2025; Dreeftoren office and residential phases in FY2025 and FY2026; Sydney CTC in FY2027; and Meerparc in FY2028.
PRC property-financing loans are expected to decline further in 2H2024 as maturities fall due and new lending remains cautious.
Puccini Milan and Le Méridien Frankfurt renovation works were expected to start in 2H2024; Puccini hotel operations are targeted for 2H2025.
Latest events from First Sponsor
- European income grew as PRC presales stayed weak; NSI profit and S$244m rights proceeds bolstered 3Q.ADN
Q3 2024 TU - FY2023 profit fell 90.5% as European property income and equity proceeds supported resilience.ADN
H2 2023 - European income and hotel earnings improved as PRC property demand stayed weak.ADN
Q1 2024 TU - NSI earnings lifted FY2024 profit despite PRC weakness and impairment charges.ADN
H2 2024 - Weak PRC presales contrast with stable European income and progress on loan recovery.ADN
Q1 2025 - Attributable profit rose 59.2% despite lower revenue and subdued PRC pre-sales.ADN
H1 2025 - Loan recovery and refinancing bolster flexibility as PRC sales stay weak and European income edges higher.ADN
Q3 2025 TU - Derivative losses drove FY2025 reported loss despite adjusted profit and stronger European hotels.ADN
H2 2025 - H1 attributable loss reached S$92.8m as derivatives and Humen impairment offset European NOI growth.ADN
H1 2026